Study shows iMDx test equivalent to NGS kits for dd-cfDNA measurement in kidney transplant patients, supporting future commercialization efforts. Results from a head-to-head comparison show iMDx's ...

AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NTRA) (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the American Journal of Transplantation (AJT) ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the publication of two major studies, DTRT-2 and Trifecta-Heart, ...

Validation study published in the Journal of the American Society of Nephrology (JASN) showed improved sensitivity with quantification vs. dd-cfDNA fraction alone AUSTIN, Texas, Sept. 9, 2021 ...

Researchers at the National Institutes of Health (NIH) found previously undetected cancers in 48.6% of pregnant people who had abnormal results for prenatal cell-free DNA (cfDNA) testing used to ...

Study indicates iMDx flagship technology’s equivalence with commercially available dd-cfDNA test kits Head-to-head comparison of iMDx’s digital PCR-based test kits with NGS kits shows consistent ...

A blood test known as a cfDNA test has proven to be accurate in detecting colorectal cancer in the majority of cases. Colorectal cancer is often deadly, but screening for it can be inconvenient, so ...

A DNA screening to look for fetal abnormalities can render some unexpected results. According to a new analysis, a cell-free DNA screening to test for chromosomal disorders can also reveal undetected ...